Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors
20 January 2022 - 10:30PM
Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage
biopharmaceutical company developing a new class of complement
medicines for patients with classical complement-mediated
autoimmune, neurodegenerative, and ophthalmic disorders, today
announced the appointment of biotech executive Bettina M. Cockroft,
M.D., senior vice president and chief medical officer of Sangamo
Therapeutics, Inc., to the company’s board of directors.
“We are very pleased to welcome Bettina to the Annexon board of
directors, as she brings extensive experience leading clinical
organizations with a focus on neurodegenerative and movement
disorders,” said Douglas Love, Esq., president and chief executive
officer of Annexon. “This is an exciting period for Annexon, and
Bettina’s expertise will be invaluable as we work toward advancing
our novel complement-focused therapies for patients in need.”
“Annexon has built an impressive pipeline of therapies for
patients with classical compliment-mediated disorders in the body,
brain, and eye,” said Dr. Cockroft. “The data generated across the
pipeline to-date, including in two very challenging indications
like Guillain–Barré Syndrome (GBS) and Huntington’s Disease (HD),
is promising, and with multiple data readouts anticipated over the
next two years, I am excited to partner with the board and senior
management team to bring forward important therapies that address
complement-mediated diseases.”
Dr. Cockroft joins the Annexon board of directors with nearly 20
years of experience in senior management roles in the
biopharmaceutical industry and has worked across multiple
therapeutic areas and led programs in several countries. Dr.
Cockroft has served as senior vice president and chief medical
officer of Sangamo since September 2019 and oversees all clinical
development activities and operations. Prior to Sangamo, Dr.
Cockroft served on the senior leadership team at Cytokinetics,
Inc., where she was responsible for clinical development of fast
skeletal muscle troponin activators in diseases such as amyotrophic
lateral sclerosis and spinal muscular atrophy. Before that, Dr.
Cockroft served as chief medical officer of Auris Medical AG, where
she led and grew the clinical development team responsible for two
Phase 3 programs. Dr. Cockroft also held roles of increasing
responsibility at Merck Serono S.A., Novartis Consumer Health and
Menarini Ricerche earlier in her career. Dr. Cockroft earned her
MBA at MIT Sloan School of Management and her M.D. from the
University of Genova.
About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical
company developing a new class of complement medicines for patients
with classical complement-mediated autoimmune, neurodegenerative,
and ophthalmic disorders of the body, brain, and eye. The company’s
pipeline is based on its platform technology addressing a broad
spectrum of well-researched classical complement-mediated
autoimmune and neurodegenerative diseases triggered by aberrant
activation of C1q, the initiating molecule of the classical
complement pathway. Annexon is advancing a portfolio of innovative
product candidates designed to block the activity of C1q and the
entire classical complement pathway: ANX005 (intravenous
administration), ANX007 (intravitreal administration), and ANX009
(subcutaneous administration). Annexon is deploying a disciplined,
biomarker-driven strategy designed to improve the probability of
technical success of its portfolio. For more information,
visit www.annexonbio.com.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Sheryl SeapyReal
Chemistry949-903-4750sseapy@realchemistry.com
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From Apr 2023 to Apr 2024